These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30511542)

  • 1. Attitudes of physicians concerning vaccines not included in the national immunization schedule.
    Çataklı T; Duyan-Çamurdan A; Aksakal-Baran FN; Güven AE; Beyazova U
    Turk J Pediatr; 2018; 60(3):290-297. PubMed ID: 30511542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.
    Walker TY; Elam-Evans LD; Yankey D; Markowitz LE; Williams CL; Mbaeyi SA; Fredua B; Stokley S
    MMWR Morb Mortal Wkly Rep; 2018 Aug; 67(33):909-917. PubMed ID: 30138305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020.
    Pingali C; Yankey D; Elam-Evans LD; Markowitz LE; Williams CL; Fredua B; McNamara LA; Stokley S; Singleton JA
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(35):1183-1190. PubMed ID: 34473682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2019.
    Elam-Evans LD; Yankey D; Singleton JA; Sterrett N; Markowitz LE; Williams CL; Fredua B; McNamara L; Stokley S
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1109-1116. PubMed ID: 32817598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Aug; 62(34):685-93. PubMed ID: 23985496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.
    Reagan-Steiner S; Yankey D; Jeyarajah J; Elam-Evans LD; Singleton JA; Curtis CR; MacNeil J; Markowitz LE; Stokley S
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(29):784-92. PubMed ID: 26225476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician communication about adolescent vaccination: How is human papillomavirus vaccine different?
    Gilkey MB; Moss JL; Coyne-Beasley T; Hall ME; Shah PD; Brewer NT
    Prev Med; 2015 Aug; 77():181-5. PubMed ID: 26051197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Use of Human Papillomavirus and Other Adolescent Vaccines in the United States.
    Vielot NA; Butler AM; Brookhart MA; Becker-Dreps S; Smith JS
    J Adolesc Health; 2017 Sep; 61(3):281-287. PubMed ID: 28739327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
    Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
    Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013.
    Elam-Evans LD; Yankey D; Jeyarajah J; Singleton JA; Curtis RC; MacNeil J; Hariri S; ;
    MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):625-33. PubMed ID: 25055186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-level assessment of factors associated with uptake of adolescent-targeted vaccines in Michigan.
    Gowda C; Dong S; Potter RC; Dombkowski KJ; Dempsey AF
    J Adolesc Health; 2013 Oct; 53(4):498-505. PubMed ID: 24054080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016.
    Walker TY; Elam-Evans LD; Singleton JA; Yankey D; Markowitz LE; Fredua B; Williams CL; Meyer SA; Stokley S
    MMWR Morb Mortal Wkly Rep; 2017 Aug; 66(33):874-882. PubMed ID: 28837546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.
    Rivera L; Chanthavanich P; Põder A; Suryakiran PV; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(27):3967-3975. PubMed ID: 29789243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant HPV and MenACWY vaccination among sixth and seventh graders receiving Tdap.
    Doke K; Fitzgerald SA; Barral RL; Griffin P; Ellerbeck EF
    Vaccine; 2018 Oct; 36(45):6819-6825. PubMed ID: 30266487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
    Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
    Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
    Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender of the Clinician, Child, and Guardian and the Association With Receipt of Routine Adolescent Vaccines.
    Faherty LJ; French B; Fiks AG
    J Adolesc Health; 2016 Jul; 59(1):116-22. PubMed ID: 27188630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Aug; 61(34):671-7. PubMed ID: 22932301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.